Djibouti
Tuberculosis profile
| High HIV burden |
Population  2012 <1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.66 (0.28–1.2) 76 (33–139)
Mortality (HIV+TB only) 0.15 (0.12–0.17) 17 (14–19)
Prevalence  (includes HIV+TB) 7.7 (3.6–13) 897 (418–1 555)
Incidence  (includes HIV+TB) 5.3 (4.4–6.3) 620 (512–738)
Incidence (HIV+TB only) 0.54 (0.45–0.64) 63 (52–75)
Case detection, all forms (%) 65 (55–79)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 170 (36) Relapse 190 (73)
Smear-negative 547 (17) Treatment after failure 61 (23)
Smear-unknown / not done     Treatment after default 11 (4)
Extrapulmonary 1 567 (48) Other    
Other          
Total new 3 284   Total retreatment 262  
           
Other (history unknown)          
Total new and relapse 3 474   Total cases notified 3 546  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.9    
Age < 15 42    
Laboratories 2012
Smear (per 100 000 population) 2.1
Culture (per 5 million population) 5.8
Drug susceptibility testing (per 5 million population) 5.8
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 82   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary    
Retreatment 63  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 289 (36)
HIV-positive TB patients 130 (10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 83 (64)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 0  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
31 (2–58) 50 (19–81)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases     96
Patients started on MDR-TB treatment     65
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically  
% Funded internationally 71%
% Unfunded 29%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data